Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis

Akiko Wakuta, Kazuhiro Nouso, Kazuya Kariyama, Mamoru Nishimura, Masayuki Kishida, Nozomu Wada, Takaaki Mizushima, Toshihiro Higashi, Mitsune Tanimoto

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Radiofrequency ablation (RFA) is used to treat early-stage hepatocellular carcinoma (HCC), but is sometimes avoided in patients with decompensated liver cirrhosis because of the possible side effect of deterioration of liver function. Aims: In this study, we report the safety and effects of RFA for treating HCC patients with Child-Pugh B/C liver cirrhosis. Methods: Sixty-six consecutive HCC patients with Child-Pugh B/C cirrhosis, who were treated by RFA, were enrolled in this study. We analyzed patient outcomes, the complications of RFA, and changes in liver function and tumor markers. Results: Fifty-six patients were classified as Child-Pugh class B, and 10 were classified as class C. The overall survival rates in patients with Child-Pugh B and C cirrhosis were 82 and 83% at 1 year and 47 and 31% at 3 years, respectively. Serum total bilirubin (T.Bil), albumin, prothrombin time, ascites, and encephalopathy were unchanged at 1, 3, and 6 months after RFA in patients with Child-Pugh B cirrhosis; however, serum T.Bil levels increased significantly at 6 months after RFA in 6/10 (60%) patients with Child-Pugh C cirrhosis. Hemothorax and rupture of esophageal varices were observed in 2 patients; however, there were no complications related to poor liver function. Conclusion: RFA is a useful modality for treating HCC in patients with poor liver function such as Child-Pugh B and C, but careful monitoring after RFA must be needed.

Original languageEnglish
Pages (from-to)39-44
Number of pages6
JournalOncology
Volume81
Issue number1
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Hepatocellular Carcinoma
Fibrosis
Therapeutics
Liver
Bilirubin
Liver Cirrhosis
Hemothorax
Esophageal and Gastric Varices
Prothrombin Time
Brain Diseases
Tumor Biomarkers
Serum
Ascites
Rupture
Albumins
Survival Rate
Safety

Keywords

  • Decompensated cirrhosis
  • Hepatocellular carcinoma
  • Radiofrequency ablation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wakuta, A., Nouso, K., Kariyama, K., Nishimura, M., Kishida, M., Wada, N., ... Tanimoto, M. (2011). Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis. Oncology, 81(1), 39-44. https://doi.org/10.1159/000331411

Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis. / Wakuta, Akiko; Nouso, Kazuhiro; Kariyama, Kazuya; Nishimura, Mamoru; Kishida, Masayuki; Wada, Nozomu; Mizushima, Takaaki; Higashi, Toshihiro; Tanimoto, Mitsune.

In: Oncology, Vol. 81, No. 1, 09.2011, p. 39-44.

Research output: Contribution to journalArticle

Wakuta, A, Nouso, K, Kariyama, K, Nishimura, M, Kishida, M, Wada, N, Mizushima, T, Higashi, T & Tanimoto, M 2011, 'Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis', Oncology, vol. 81, no. 1, pp. 39-44. https://doi.org/10.1159/000331411
Wakuta A, Nouso K, Kariyama K, Nishimura M, Kishida M, Wada N et al. Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis. Oncology. 2011 Sep;81(1):39-44. https://doi.org/10.1159/000331411
Wakuta, Akiko ; Nouso, Kazuhiro ; Kariyama, Kazuya ; Nishimura, Mamoru ; Kishida, Masayuki ; Wada, Nozomu ; Mizushima, Takaaki ; Higashi, Toshihiro ; Tanimoto, Mitsune. / Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis. In: Oncology. 2011 ; Vol. 81, No. 1. pp. 39-44.
@article{4c9eb4daee384d35aa1f088499d5cba8,
title = "Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis",
abstract = "Background: Radiofrequency ablation (RFA) is used to treat early-stage hepatocellular carcinoma (HCC), but is sometimes avoided in patients with decompensated liver cirrhosis because of the possible side effect of deterioration of liver function. Aims: In this study, we report the safety and effects of RFA for treating HCC patients with Child-Pugh B/C liver cirrhosis. Methods: Sixty-six consecutive HCC patients with Child-Pugh B/C cirrhosis, who were treated by RFA, were enrolled in this study. We analyzed patient outcomes, the complications of RFA, and changes in liver function and tumor markers. Results: Fifty-six patients were classified as Child-Pugh class B, and 10 were classified as class C. The overall survival rates in patients with Child-Pugh B and C cirrhosis were 82 and 83{\%} at 1 year and 47 and 31{\%} at 3 years, respectively. Serum total bilirubin (T.Bil), albumin, prothrombin time, ascites, and encephalopathy were unchanged at 1, 3, and 6 months after RFA in patients with Child-Pugh B cirrhosis; however, serum T.Bil levels increased significantly at 6 months after RFA in 6/10 (60{\%}) patients with Child-Pugh C cirrhosis. Hemothorax and rupture of esophageal varices were observed in 2 patients; however, there were no complications related to poor liver function. Conclusion: RFA is a useful modality for treating HCC in patients with poor liver function such as Child-Pugh B and C, but careful monitoring after RFA must be needed.",
keywords = "Decompensated cirrhosis, Hepatocellular carcinoma, Radiofrequency ablation",
author = "Akiko Wakuta and Kazuhiro Nouso and Kazuya Kariyama and Mamoru Nishimura and Masayuki Kishida and Nozomu Wada and Takaaki Mizushima and Toshihiro Higashi and Mitsune Tanimoto",
year = "2011",
month = "9",
doi = "10.1159/000331411",
language = "English",
volume = "81",
pages = "39--44",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis

AU - Wakuta, Akiko

AU - Nouso, Kazuhiro

AU - Kariyama, Kazuya

AU - Nishimura, Mamoru

AU - Kishida, Masayuki

AU - Wada, Nozomu

AU - Mizushima, Takaaki

AU - Higashi, Toshihiro

AU - Tanimoto, Mitsune

PY - 2011/9

Y1 - 2011/9

N2 - Background: Radiofrequency ablation (RFA) is used to treat early-stage hepatocellular carcinoma (HCC), but is sometimes avoided in patients with decompensated liver cirrhosis because of the possible side effect of deterioration of liver function. Aims: In this study, we report the safety and effects of RFA for treating HCC patients with Child-Pugh B/C liver cirrhosis. Methods: Sixty-six consecutive HCC patients with Child-Pugh B/C cirrhosis, who were treated by RFA, were enrolled in this study. We analyzed patient outcomes, the complications of RFA, and changes in liver function and tumor markers. Results: Fifty-six patients were classified as Child-Pugh class B, and 10 were classified as class C. The overall survival rates in patients with Child-Pugh B and C cirrhosis were 82 and 83% at 1 year and 47 and 31% at 3 years, respectively. Serum total bilirubin (T.Bil), albumin, prothrombin time, ascites, and encephalopathy were unchanged at 1, 3, and 6 months after RFA in patients with Child-Pugh B cirrhosis; however, serum T.Bil levels increased significantly at 6 months after RFA in 6/10 (60%) patients with Child-Pugh C cirrhosis. Hemothorax and rupture of esophageal varices were observed in 2 patients; however, there were no complications related to poor liver function. Conclusion: RFA is a useful modality for treating HCC in patients with poor liver function such as Child-Pugh B and C, but careful monitoring after RFA must be needed.

AB - Background: Radiofrequency ablation (RFA) is used to treat early-stage hepatocellular carcinoma (HCC), but is sometimes avoided in patients with decompensated liver cirrhosis because of the possible side effect of deterioration of liver function. Aims: In this study, we report the safety and effects of RFA for treating HCC patients with Child-Pugh B/C liver cirrhosis. Methods: Sixty-six consecutive HCC patients with Child-Pugh B/C cirrhosis, who were treated by RFA, were enrolled in this study. We analyzed patient outcomes, the complications of RFA, and changes in liver function and tumor markers. Results: Fifty-six patients were classified as Child-Pugh class B, and 10 were classified as class C. The overall survival rates in patients with Child-Pugh B and C cirrhosis were 82 and 83% at 1 year and 47 and 31% at 3 years, respectively. Serum total bilirubin (T.Bil), albumin, prothrombin time, ascites, and encephalopathy were unchanged at 1, 3, and 6 months after RFA in patients with Child-Pugh B cirrhosis; however, serum T.Bil levels increased significantly at 6 months after RFA in 6/10 (60%) patients with Child-Pugh C cirrhosis. Hemothorax and rupture of esophageal varices were observed in 2 patients; however, there were no complications related to poor liver function. Conclusion: RFA is a useful modality for treating HCC in patients with poor liver function such as Child-Pugh B and C, but careful monitoring after RFA must be needed.

KW - Decompensated cirrhosis

KW - Hepatocellular carcinoma

KW - Radiofrequency ablation

UR - http://www.scopus.com/inward/record.url?scp=80052581782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052581782&partnerID=8YFLogxK

U2 - 10.1159/000331411

DO - 10.1159/000331411

M3 - Article

C2 - 21912196

AN - SCOPUS:80052581782

VL - 81

SP - 39

EP - 44

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1

ER -